English Français

Medexus Pharmaceuticals, Inc. Medexus Pharmaceuticals, Inc.

  • English
  • About
    • Overview
    • Growth Strategy
    • Management Team
    • Board of Directors
  • Our Portfolio
    • Overview
    • Canadian Product Portfolio
    • US Product Portfolio
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentation
    • Financial Results
    • Stock Data
    • Governance
    • SEDAR
  • Contact
  • Careers
  • English
  • Français

Press Releases

News

News

  • Press Releases
  • Events
Aug 02, 2022 5:00pm EDT

Medexus Schedules First Quarter 2023 Conference Call

Jul 25, 2022 7:00am EDT

Treosulfan NDA Resubmitted to FDA

Jun 22, 2022 5:50pm EDT

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Jun 14, 2022 4:30pm EDT

Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

Jun 06, 2022 8:30am EDT

Treosulfan Pivotal Study Results Published

May 24, 2022 5:05pm EDT

Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

Apr 22, 2022 8:30am EDT

Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Apr 19, 2022 4:20pm EDT

Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference

Mar 09, 2022 8:00am EST

Medexus to Participate in the 34th Annual Roth Conference

Mar 01, 2022 7:15am EST

Medexus Pharmaceuticals Announces Deal for Gleolan in the United States

RSS
  • Previous
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...14
    Next
    © 2023 Medexus Pharmaceuticals, Inc.
    All Rights Reserved.
    Facebook Facebook
    Privacy Policy Disclaimer Sitemap

    Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.